v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses    
Research and development $ 17,197 $ 13,531
General and administrative 3,984 4,433
Total operating expenses 21,181 17,964
Loss from operations (21,181) (17,964)
Other income, net 1,118 1,409
Change in fair value of warrant liabilities (18,962) 10,060
Net loss (39,025) (6,495)
Other comprehensive loss:    
Unrealized loss on available-for-sale securities, net (96) (44)
Comprehensive loss $ (39,121) $ (6,539)
Basic earnings per share of common stock $ (0.33) $ (0.08)
Diluted earnings per share of common stock $ (0.33) $ (0.08)
Weighted-average common shares outstanding, basic 112,424,211 77,126,763
Weighted-average common shares outstanding, diluted 112,424,211 77,126,763
Series X and Series X1 Non-voting Convertible Preferred Stock [Member]    
Other comprehensive loss:    
Basic earnings per share of common stock $ (18.25) $ (4.32)
Diluted earnings per share of common stock $ (18.25) $ (4.32)
Weighted-average common shares outstanding, basic 114,508 114,508
Weighted-average common shares outstanding, diluted 114,508 114,508